Related Experiment Video
Updated: Feb 19, 2026
Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms
Published on: May 31, 2024
Synthesis, Molecular Docking and Biological Evaluation of Quinolone Derivatives as Novel Anticancer Agents
Jie Li1, Tu-Cai Zheng1, Yi Jin1
1College of Chemistry and Materials Engineering, Quzhou University.
Abstract:
A series of novel quinolone derivatives (8a-j) were synthesized, and their anticancer activities were tested in human cancer cell lines, human lung carcinoma cell (A549), human promyelocytic leukemia cell (HL-60), and human cervical cancer cell (Hela). Compound 8i was found to be 5-times more potent in cell-killing activity for cell lines A549, HL-60, and Hela than the positive control irinotecan or cisplatin, with IC50 of 0.009, 0.008 and 0.010 µM, respectively. The docking study revealed that compound 8i might have strong interactions with the active site of DNA-topoisomerase I.
Insights
Novel quinolone derivatives show potent anticancer activity. Compound 8i demonstrated superior efficacy against lung, leukemia, and cervical cancer cells compared to standard treatments.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Cancer Biology
Background:
- Quinolone derivatives are a class of compounds with diverse biological activities.
- Developing novel anticancer agents with improved efficacy and reduced toxicity is a critical area of research.
- Targeting DNA-topoisomerase I is a validated strategy in cancer chemotherapy.
Purpose of the Study:
- To synthesize and characterize a series of novel quinolone derivatives.
- To evaluate the in vitro anticancer potential of these compounds against various human cancer cell lines.
- To investigate the potential mechanism of action of the most potent derivative.
Main Methods:
- Synthesis of quinolone derivatives (8a-j) using established organic chemistry techniques.
- Anticancer activity screening using human lung carcinoma (A549), human promyelocytic leukemia (HL-60), and human cervical cancer (Hela) cell lines.
- In silico molecular docking studies to predict interactions with DNA-topoisomerase I.
Main Results:
- Compound 8i exhibited significant cytotoxic effects against A549, HL-60, and Hela cells.
- Compound 8i displayed 5-fold greater potency than irinotecan and cisplatin, with IC50 values in the nanomolar range (0.009, 0.008, and 0.010 µM, respectively).
- Docking studies suggested strong binding interactions between compound 8i and the active site of DNA-topoisomerase I.
Conclusions:
- The synthesized quinolone derivatives, particularly compound 8i, represent promising candidates for anticancer drug development.
- Compound 8i's potent activity and potential mechanism involving DNA-topoisomerase I warrant further investigation.
- This study contributes novel quinolone-based compounds for cancer therapy research.
